These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 27019793)

  • 21. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.
    Kontoghiorghes GJ
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
    Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Front Biosci (Elite Ed); 2022 Jul; 14(3):18. PubMed ID: 36137990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
    Pepe A; Meloni A; Pistoia L; Cuccia L; Gamberini MR; Lisi R; D'Ascola DG; Rosso R; Allò M; Spasiano A; Restaino G; Righi R; Mangione M; Positano V; Ricchi P
    Br J Haematol; 2018 Dec; 183(5):783-795. PubMed ID: 30334574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies.
    Kontoghiorghes GJ
    Toxicol Mech Methods; 2013 Jan; 23(1):1-4. PubMed ID: 22900514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
    Kontoghiorghes GJ
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):1-5. PubMed ID: 16503822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.
    Kontoghiorghes GJ; Kleanthous M; Kontoghiorghe CN
    Mediterr J Hematol Infect Dis; 2020; 12(1):e2020011. PubMed ID: 31934321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New targeted therapies and diagnostic methods for iron overload diseases.
    Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
    Front Biosci (Schol Ed); 2018 Jan; 10(1):1-20. PubMed ID: 28930516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterisation of individual ferritin response in patients receiving chelation therapy.
    Borella E; Oosterholt S; Magni P; Della Pasqua O
    Br J Clin Pharmacol; 2022 Aug; 88(8):3683-3694. PubMed ID: 35199367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.
    Kontoghiorghes GJ; Kolnagou A
    Curr Med Chem; 2005; 12(23):2695-709. PubMed ID: 16305466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ
    Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
    Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology.
    Kontoghiorghe CN; Kolnagou A; Kontoghiorghes GJ
    Molecules; 2015 Nov; 20(11):20841-72. PubMed ID: 26610453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
    Kontoghiorghes GJ; Spyrou A; Kolnagou A
    Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.